Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

This study is testing whether adding an immunotherapy drug (anti-PD1) to standard chemoradiotherapy can improve outcomes for patients with nasopharyngeal carcinoma (NPC — a cancer of the back of the throat) that has come back locally after previous treatment. **You may be eligible if...** - Your NPC came back in the same local/regional area, at least 1 year after your original treatment - Surgery is not an option for you - Your recurrent cancer is stage rII–IVa - You have not received any treatment for this recurrence yet - Your blood counts and organ function (liver, kidneys, bone marrow) meet the required levels - You are generally active and functional (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have received any prior treatment for this recurrence - You have contraindications to immunotherapy or chemoradiotherapy Talk to your doctor to see if this trial is right for you.